The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Open accessAbstract
The embryonic pyruvate kinase M2 (PKM2) isoform is highly expressed in human cancer. In contrast to the established role of PKM2 in aerobic glycolysis or the Warburg effect, its non-metabolic functions remain elusive. Here we demonstrate, in human cancer cells, that epidermal growth factor receptor (EGFR) activation induces translocation of PKM2, but not PKM1, into the nucleus, where K433 of PKM2 binds to c-Src-phosphorylated Y333 of β-catenin. This interaction is required for both proteins to be recruited to the CCND1 promoter, leading to HDAC3 removal from the promoter, histone H3 acetylation and cyclin D1 expression. PKM2-dependent β-catenin transactivation is instrumental in EGFR-promoted tumour cell proliferation and brain tumour development. In addition, positive correlations have been identified between c-Src activity, β-catenin Y333 phosphorylation and PKM2 nuclear accumulation in human glioblastoma specimens. Furthermore, levels of β-catenin phosphorylation and nuclear PKM2 have been correlated with grades of glioma malignancy and prognosis. These findings reveal that EGF induces β-catenin transactivation via a mechanism distinct from that induced by Wnt/Wingless and highlight the essential non-metabolic functions of PKM2 in EGFR-promoted β-catenin transactivation, cell proliferation and tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 1×
“Our findings, in combination with previous reports(7,24), delineate two essential mechanisms underlying tumour development by regulation of metabolic and non-metabolic functions of PKM2: (1) PKM2 enhances aerobic glycolysis(7,24); and (2) PKM2 promotes tumour cell proliferation by binding to and transactivating Y333-p…”
Resultβ-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Self-citationThe M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
Pyruvate kinase M2 is a phosphotyrosine-binding protein
Christofk, H. R., Vander Heiden, M. G., Wu, N., Asara, J. M., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06667 · Cited by 995
Phosphorylation of β-Catenin by AKT Promotes β-Catenin Transcriptional Activity
Fang, D., Hawke, D., Zheng, Y., Xia, Y., Meisenhelder, J., Nika, H., Mills, G. B., Kobayashi, R., Hunter, T., & Lu, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611871200 · Cited by 870
Self-citationGene Expression Profiling of Gliomas Strongly Predicts Survival
Freije, W. A., Castro-Vargas, F. E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L. M., Mischel, P. S., & Nelson, S. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0452 · Cited by 744
Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells
Mazurek, S. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.005 · Cited by 694
Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology
Gravendeel, L. A. M., Kouwenhoven, M. C. M., Gevaert, O., de Rooi, J. J., Stubbs, A. P., Duijm, J. E., Daemen, A., Bleeker, F. E., Bralten, L. B. C., Kloosterhof, N. K., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2307 · Cited by 678
Lu, Z., Ghosh, S., Wang, Z., & Hunter, T. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00304-0 · Cited by 647
Self-citationActivation of Protein Kinase C Triggers Its Ubiquitination and Degradation
Lu, Z., Liu, D., Hornia, A., Devonish, W., Pagano, M., & Foster, D. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.839 · Cited by 334
Self-citationLu, Z., Jiang, G., Blume-Jensen, P., & Hunter, T. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4016-4031.2001 · Cited by 329
Self-citationJi, H., Wang, J., Nika, H., Hawke, D., Keezer, S., Ge, Q., Fang, B., Fang, X., Fang, D., Litchfield, D. W., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.09.034 · Cited by 270
Self-citationBcr‐Abl stabilizes β‐catenin in chronic myeloid leukemia through its tyrosine phosphorylation
Coluccia, A. M. L., Vacca, A., Duñach, M., Mologni, L., Redaelli, S., Bustos, V. H., Benati, D., Pinna, L. A., & Gambacorti‐Passerini, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601485 · Cited by 217
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Wykosky, J., Fenton, T., Furnari, F., & Cavenee, W. K. (2011) · Chinese Journal of Cancer · doi:10.5732/cjc.010.10542 · Cited by 160
Miravet, S., Piedra, J. A., Castaño, J., Raurell, I., Francı́, C., Duñach, M., & de Herreros, A. G. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7391-7402.2003 · Cited by 111
Yochum, G. S., McWeeney, S. K., Rajaraman, V., Cleland, R., Peters, S. T., & Goodman, R. H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611576104 · Cited by 96
Petalidis, L. P., Oulas, A., Bäcklund, L. M., Wayland, M. T., Liu, L., Plant, K., Happerfield, L. C., Freeman, T. C., Poirazi, P., & Collins, V. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0177 · Cited by 93
Xia, Y., Wang, J., Liu, T.-J., Yung, W. K. A., Hunter, T. R., & Lu, Z. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.005 · Cited by 78
Self-citationWnt-independent beta-catenin transactivation in tumor development.
Lu, Z., & Hunter, T. R. (2004) · PubMed · Cited by 61
Self-citationGomez‐Manzano, C., Alonso, M. M., Yung, W. K. A., McCormick, F. P., Curiel, D. T., Lang, F. F., Jiang, H., Bekele, B. N., Zhou, X. C., Alemany, R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1892 · Cited by 51
Regulation of glycolysis by Raf protein serine/threonine kinases
Mellay, V. L., Houben, R., Troppmair, J., Hagemann, C., Mazurek, S., Frey, U. H., Beigel, J., Weber, C. K., Benz, R., EIGENBRODT, E., et al. (2002) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(01)00036-x · Cited by 46
Wnt-Independent ?-catenin Transactivation in Tumor Developement
Lu, Z., & Hunter, T. R. (2004) · Cell Cycle · doi:10.4161/cc.3.5.885 · Cited by 33
Self-citation
Cited by
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
The many faces and functions of β‐catenin
Valenta, T., Hausmann, G., & Basler, K. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.150 · Cited by 1,598
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
Palsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A. R., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W. M., Quinn, S. R., Domingo-Fernandez, R., Johnston, D. G. W., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.005 · Cited by 1,397
“Other nuclear functions of dimeric PKM2 includes the ability to act as a protein kinase, activating transcription of mek5 through phosphorylation of STAT3(Gao et al., 2012) as well as promoting β-catenin translocation, leading to expression of cyclinD1 and c-myc(Yang et al., 2011).”
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335
Metadata
- Authors
- Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., & Lu, Z.
- Venue
- Nature
- Published
- 2011-12-01
- Volume
- 480
- Issue
- 7375
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2106204137
- Cited by
- 1,028
- References
- 27
- FWCI
- 21.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.